IBRANCE® (palbociclib) capsules, for oral use
Initial U.S. Approval: 2015
Generic Name: palbociclib
Mechanism of Action: Cyclin-dependent kinase 4 (CDK4) inhibitor; Cyclin-dependent kinase 6 (CDK6) inhibitor
South Delhi Pharma can facilitate patients and physicians access to commercially approved medicines, “Ibrance (palbociclib)” to all locations in the world and in India after fulfilling the legal requirement (if applicable). Ibrance (palbociclib) is a prescription drug and should be used under proper medical guidance and advice. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
What Ibrance is?
IBRANCE is a kinase inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
• an aromatase inhibitor as initial endocrine based therapy in postmenopausal women; or
• fulvestrant in women with disease progression following endocrine therapy.
What Palbociclib is?
Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.